Chemotherapy, Adjuvant

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 'I'll do what they did": social norm information and cancer treatment decisions. 
  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 3D image guidance assisted identification of colorectal cancer liver metastases not seen on intraoperative ultrasound: results from a prospective trial. 
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. 
  • A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. 
  • A general formulation for a one-sided group sequential design. 
  • A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. 
  • A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. 
  • A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. 
  • A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. 
  • Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. 
  • Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. 
  • Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. 
  • Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 
  • Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. 
  • Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. 
  • Adjuvant Chemotherapy for Stage II Rectal Cancer. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. 
  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. 
  • Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. 
  • Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making. 
  • Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. 
  • Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit. 
  • Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. 
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant high-dose interferon therapy for high-risk melanoma. 
  • Adjuvant hormonal therapy use among insured, low-income women with breast cancer. 
  • Adjuvant hormonal therapy use among women with ductal carcinoma in situ. 
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. 
  • Adjuvant therapy for colorectal cancer. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adjuvant therapy for pancreatic cancer: an evolving paradigm. 
  • Adjuvant therapy for pancreatic cancer: current status and future directions. 
  • Adjuvant therapy for surgically resected pancreatic adenocarcinoma. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Adjuvant therapy of pancreatic cancer. 
  • Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. 
  • Adjuvant trazodone in the treatment of alcoholism: an open study. 
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 
  • Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
  • Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. 
  • Aggressive multimodality treatment of invasive thymic carcinoma. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • Anal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. 
  • Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. 
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. 
  • Applying the neoadjuvant paradigm to ductal carcinoma in situ. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. 
  • Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. 
  • Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. 
  • Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. 
  • Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. 
  • BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. 
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. 
  • Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. 
  • Bladder cancer. Clinical practice guidelines in oncology. 
  • Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. 
  • CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: three case studies and a review of the literature. 
  • Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. 
  • Cardiorespiratory fitness in breast cancer patients: a call for normative values. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. 
  • Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. 
  • Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. 
  • Chemoradiation for localized pancreatic cancer: another perspective. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. 
  • Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. 
  • Chemotherapy for adults with malignant glioma. 
  • Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Clear cell adenocarcinoma in a female urethral diverticulum. 
  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. 
  • Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. 
  • Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. 
  • Clinicopathologic factors and adjuvant treatment effects on survival in adult head and neck synovial cell sarcoma. 
  • Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. 
  • Clinicopathological characteristics and treatment of rhabdoid glioblastoma. 
  • Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). 
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). 
  • Colorectal cancer. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combined modality therapy for rectal and colon cancer. 
  • Combined modality treatment for rectal cancer. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. 
  • Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. 
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). 
  • Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. 
  • Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. 
  • Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. 
  • Congenital neuroepithelioma in an infant hand. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. 
  • Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis. 
  • Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. 
  • Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. 
  • Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. 
  • Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. 
  • Current Trends in the Management of Ductal Carcinoma In Situ. 
  • Current management of adrenal tumors. 
  • Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. 
  • Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. 
  • Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions. 
  • Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. 
  • Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer. 
  • Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? 
  • Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. 
  • Desmoid tumors of the chest wall. 
  • Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. 
  • Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer. 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Does vocal cord fixation preclude nonsurgical management of laryngeal cancer? 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. 
  • Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. 
  • Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. 
  • Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 
  • Effects of chemotherapy and tamoxifen on cervical and vaginal smears in bone marrow transplant recipients. 
  • Efficacy of autologous blood injection for treating overfiltering or leaking blebs after glaucoma surgery. 
  • Endocrine therapy in early-stage breast cancer care: defining the appropriate regimen and time frame. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. 
  • Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. 
  • Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. 
  • Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. 
  • Ewing's sarcoma of the hand. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. 
  • Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Fibromatoses in childhood: the desmoid/fibromatosis complex. 
  • Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. 
  • Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. 
  • Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. 
  • Gefitinib therapy for non-small cell lung cancer. 
  • Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. 
  • Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. 
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. 
  • Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 
  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. 
  • Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. 
  • Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. 
  • Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. 
  • Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. 
  • Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? 
  • Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. 
  • Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. 
  • Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. 
  • Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. 
  • Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. 
  • Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improving understanding of adjuvant therapy options by using simpler risk graphics. 
  • Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Individual responses to chemotherapy-induced oxidative stress. 
  • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). 
  • Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. 
  • Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. 
  • Initiation of salvage therapy for prostate cancer. 
  • Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. 
  • Invited commentary. 
  • Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy? 
  • Is NNT AOK? 
  • Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? 
  • Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. 
  • Isolated tumor cells in breast cancer. 
  • Keloid Excision and Adjuvant Treatments: A Network Meta-analysis. 
  • Laser suture lysis after mitomycin C trabeculectomy. 
  • Leiomyosarcoma in childhood and adolescence. 
  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. 
  • Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. 
  • Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. 
  • Liver metastases from breast cancer: long-term survival after curative resection. 
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy. 
  • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). 
  • Locally advanced pancreatic cancer. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. 
  • Long-term results of therapy for stage C neuroblastoma. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Long-term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. 
  • Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). 
  • MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. 
  • MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. 
  • Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. 
  • Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. 
  • Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. 
  • Melanoma, version 2.2013: featured updates to the NCCN guidelines. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. 
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 
  • Minimally invasive gastrectomy for gastric cancer: A national perspective on oncologic outcomes and overall survival. 
  • Minimally invasive operation for breast cancer. 
  • Mitomycin C-augumented trabeculectomy with postoperative wound modulation in pediatric glaucoma. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Molecular prediction of recurrence of breast cancer. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. 
  • Multiple myeloma. 
  • Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Myeloid growth factors. 
  • NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 
  • Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. 
  • Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. 
  • Never too old? Age should not be a barrier to enrollment in cancer clinical trials. 
  • Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Non-vena cava venous leiomyosarcomas: a review of the literature. 
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. 
  • Novel intronic DICER1 variation associated with pleuropulmonary blastoma in two siblings. 
  • Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). 
  • ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. 
  • Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). 
  • Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. 
  • Outcomes in surgical stage I uterine papillary serous carcinoma. 
  • Ovarian cancer, version 3.2012. 
  • Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. 
  • Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. 
  • Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Pediatric melanoma. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. 
  • Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. 
  • Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 
  • Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Phase I evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. 
  • Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. 
  • Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative concurrent chemotherapy and radiotherapy in rectal cancer patients. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Preoperative radiotherapy for rectal cancer: benefits and controversies. 
  • Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. 
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? 
  • Primary pediatric intraspinal sarcomas. Report of 3 cases. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. 
  • Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. 
  • Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. 
  • Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma. 
  • Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. 
  • Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. 
  • Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). 
  • Publication policy, informed consent, and the randomized clinical trial. 
  • Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. 
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. 
  • Quality of life after adjuvant chemotherapy for breast cancer. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. 
  • Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Radiation and chemotherapy in the treatment of esophageal cancer. 
  • Radiation therapy in the treatment of cholangiocarcinoma. 
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. 
  • Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin. 
  • Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). 
  • Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 
  • Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. 
  • Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. 
  • Regional spread of cutaneous squamous cell carcinoma of the face via facial vein tumor thrombus: a case report. 
  • Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. 
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. 
  • Response to Letter to the Editor: "The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma". 
  • Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. 
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. 
  • Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. 
  • Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. 
  • Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Role of autotransplantation in treatment of other solid tumors. 
  • Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. 
  • Role of radiation therapy in patients with resectable pancreatic cancer. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Routine use of zoledronic acid in early-stage breast cancer. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. 
  • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. 
  • Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist. 
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. 
  • Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. 
  • Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Squamous cell carcinoma of the oropharynx and hypopharynx. 
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. 
  • Staging of pancreatic cancer before and after neoadjuvant chemoradiation. 
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. 
  • Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. 
  • Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. 
  • Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children. 
  • Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. 
  • Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. 
  • Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). 
  • Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 
  • Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. 
  • Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. 
  • Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment. 
  • Synchronous colorectal liver metastases: the "surgeon as oncologist" perspective. 
  • Systemic chemotherapy for urothelial cancer. 
  • Systemic therapy for older women with breast cancer. 
  • T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Technical advances in the treatment of patients with rectal cancer. 
  • Testicular cancer. Clinical practice guidelines. 
  • Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). 
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). 
  • The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. 
  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. 
  • The benefits of discussing adjuvant therapies one at a time instead of all at once. 
  • The clinical management of chondrosarcoma. 
  • The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. 
  • The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. 
  • The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. 
  • The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. 
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants. 
  • The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer. 
  • The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). 
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The significance of distant metastases in breast cancer. 
  • The surgeon and adjuvant therapy for stage II colon cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. 
  • Thirty years of rectal cancer research: a brief history. 
  • Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. 
  • Thrombosis and drug-eluting stents: an objective appraisal. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. 
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. 
  • Total neoadjuvant therapy for rectal cancer: An emerging option. 
  • Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. 
  • Treatment and outcome of 82 patients with angiosarcoma. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of newly diagnosed glioblastoma multiforme. 
  • Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Treatment-induced changes in vocal cord mobility and subsequent local recurrence after organ preservation therapy for laryngeal carcinoma. 
  • Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. 
  • Undertreatment of obese women receiving breast cancer chemotherapy. 
  • Update on combined-modality treatment options for pancreatic cancer. 
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. 
  • Updates in adjuvant systemic therapy for melanoma. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. 
  • Use of molecular biomarkers to inform adjuvant therapy for colon cancer. 
  • Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. 
  • Vinorelbine (Navelbine) in non-small cell lung cancer: future directions. 
  • Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. 
  • Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? 
  • Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma. 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • What's new in neoadjuvant therapy for breast cancer? 
  • White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. 
  • White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. 
  • Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? 
  • Women's experiences with genomic testing for breast cancer recurrence risk. 
  • Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • [Primary chemotherapy in the treatment of breast cancer]. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
  • p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cohen, Seth Morris, Associate Professor of Head and Neck Surgery and Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Professor Emeritus of Head and Neck Surgery and Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • Lee, Walter T, Associate Professor of Head and Neck Surgery and Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology